Factors Affecting Initial Humoral Immune Response to SARS-Cov-2 Vaccines among Patients with Inflammatory Bowel Diseases

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Michael D. Kappelman ◽  
Kimberly N. Weaver ◽  
Xian Zhang ◽  
Xiangfeng Dai ◽  
Runa Watkins ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Inflammatory Bowel Diseases ◽  
Factors Affecting ◽  
Humoral Immune ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Determinants of Sleep Quality in Inflammatory Bowel Diseases

2020 ◽  
Vol 9 (9) ◽  
pp. 2921 ◽  
Author(s):  
Marcin Sochal ◽  
Ewa Małecka-Panas ◽  
Agata Gabryelska ◽  
Renata Talar-Wojnarowska ◽  
Bartosz Szmyd ◽  
...  
Keyword(s):  
Sleep Quality ◽  
Inflammatory Bowel Diseases ◽  
Pain Scale ◽  
Factors Affecting ◽  
Athens Insomnia Scale ◽  
Pain Scales ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Comorbid Chronic Diseases ◽  
Sleep Questionnaires

The causes of disordered sleep, frequently reported by patients with inflammatory bowel diseases (IBD), are poorly understood. The study aimed to evaluate sleep quality in IBD patients and to identify factors affecting their sleep. IBD patients (n = 133) and healthy controls (HC; n = 57) were included in the study and completed sleep questionnaires (Pittsburgh Sleep Quality Index (PSQI), Athens insomnia scale (AIS), and Epworth sleepiness scale (ESS)), Beck Depression Inventory (BDI), and pain scales (Visual Analogue Scale and Laitinen Pain Scale). IBD patients attained higher scores in all sleep questionnaires compared to HC: PSQI, AIS, and ESS (all p < 0.001). They also had prolonged sleep latency (p < 0.001) with reduced sleep efficiency (p < 0.001). Patients in exacerbation of IBD had higher scores in PSQI (p = 0.008), ESS (p = 0.009), but not in AIS, compared to those in remission. Participants with comorbid chronic diseases had higher scores in PSQI and AIS, but not in ESS, compared to others. Multiple regression revealed that the sleep questionnaire results were significantly affected by mood level (BDI), but not by the aforementioned pain scales. Sleep impairment in IBD patients is a common problem that deserves attention in everyday clinical practice and mood level seems to be the main factor affecting the quality of sleep in IBD patients.

Humoral immune response to intestinal microbiota in inflammatory bowel disease

2013 ◽  
Vol 24 ◽  
pp. e87-e88
Author(s):  
D. Mukhametova ◽  
D. Abdulganieva ◽  
O. Zinkevich ◽  
N. Saphina ◽  
A. Odintsova
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune Response ◽  
Intestinal Microbiota ◽  
Humoral Immune Response ◽  
Bowel Disease ◽  
Humoral Immune ◽  
Inflammatory Bowel

Probiotics and bowel inflammation

2006 ◽  
Vol 247 ◽  
pp. 1-4
Keyword(s):  
Ulcerative Colitis ◽  
Immune Response ◽  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Inflammatory Bowel Diseases ◽  
Safety Issues ◽  
Bowel Diseases ◽  
Inflammatory Bowel

In a nutshellInflammatory bowel diseases can involve problems in the development of the gut's immune response. A healthy bowel flora plays an important role in this development, for example through effects on cytokines.Clinical trials of probiotics for IBD have been predominantly positive for ulcerative colitis and pouchitis, less so for Crohn's disease. So far probiotics appear to be a notably safe therapy, although some theoretical safety issues need to be borne in mind.

scholarly journals Campylobacter concisus

2021 ◽  
Vol 15 (09) ◽  
pp. 1216-1221
Author(s):  
Biljana Miljković-Selimović ◽  
Tatjana Babić ◽  
Branislava Kocić ◽  
Ema Aleksić ◽  
Adam Malešević ◽  
...  
Keyword(s):  
Immune Response ◽  
Periodontal Disease ◽  
Inflammatory Bowel Diseases ◽  
Etiological Agent ◽  
Healthy Individuals ◽  
Campylobacter Concisus ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Campylobacter concisus has been described as the etiological agent of periodontal disease, inflammatory bowel diseases, and enterocolitis. It is also detected in healthy individuals. There are differences between strains in healthy individuals and affected ones by production of two exototoxins. In this mini review authors discuss major facts about cultivation, isolation, virulence and immune response to C. concisus.

Factors affecting vitamin D deficiency in active inflammatory bowel diseases

2019 ◽  
Vol 51 (5) ◽  
pp. 657-662 ◽  
Author(s):  
Giorgia Burrelli Scotti ◽  
Maria Teresa Afferri ◽  
Aurora De Carolis ◽  
Valentina Vaiarello ◽  
Valeria Fassino ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Inflammatory Bowel Diseases ◽  
Factors Affecting ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα

2021 ◽  
Author(s):  
Hadar Edelman-Klapper ◽  
Eran Zittan ◽  
Ariella Bar-Gil Shitrit ◽  
Keren Masha Rabinowitz ◽  
Idan Goren ◽  
...  
Keyword(s):  
Immune Response ◽  
Inflammatory Bowel Diseases ◽  
Vaccine Dose ◽  
Drug Levels ◽  
Vaccine Responses ◽  
Tnf Α ◽  
Vaccine Booster ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Administration Timing

Background: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics are at high risk for vaccine preventable infections. Their ability to mount adequate vaccine responses is unclear. Aim: to assess immune responses to mRNA-COVID-19 vaccine, and safety profile, in patients with IBD stratified according to therapy, compared to healthy controls (HC). Methods: Prospective, controlled, multi-center Israeli study. Subjects enrolled received two BNT162b2 (Pfizer/BioNTech) doses. Anti-spike (S) antibodies levels and functional activity, anti-TNFα levels and adverse events (AEs) were detected longitudinaly. Results: Overall 258 subjects: 185 IBD (67 treated with anti-TNFα), and 73 HC. After the first vaccine dose all HC were seropositive, while some patients with IBD, regardless of treatment, remained seronegative. After the second dose all subjects were seropositive, however anti-S levels were significantly lower in anti-TNFα treated compared to untreated patients, and HC (p<0.001; p<0.001, respectively). Neutralizing and inhibitory functions were both lower in anti-TNFα treated compared to untreated patients, and HC (p<0.03; p<0.0001, respectively). Anti-TNFα drug levels and vaccine responses did not affect anti-S levels. Infection rate (~2%) and AEs were comparable in all groups. IBD activity did not change in response to BNT162b2. Conclusions: In this prospective study in patients with IBD stratified according to treatment all patients mounted an immune response to two doses of BNT162b2. However, its magnitude was significantly lower in patients treated with anti-TNFα, regardless of administration timing and drug levels. Vaccine was safe. As vaccine immune response longevity in this group may be limited, vaccine booster dose should be considered.

Sign in / Sign up

Export Citation Format

Share Document